Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma.

MLA

Federici, Carlo, et al. “Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma.” Clinical Therapeutics, vol. 44, no. 11, Nov. 2022, pp. 1480–93. EBSCOhost, https://doi.org/10.1016/j.clinthera.2022.09.006.

APA

Federici, C., Rognoni, C., Costa, F., Armeni, P., Crovato, E., & Bellucci, S. (2022). Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma. Clinical Therapeutics, 44(11), 1480–1493. https://doi.org/10.1016/j.clinthera.2022.09.006

Chicago

Federici, Carlo, Carla Rognoni, Francesco Costa, Patrizio Armeni, Elisa Crovato, and Stefania Bellucci. 2022. “Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma.” Clinical Therapeutics 44 (11): 1480–93. doi:10.1016/j.clinthera.2022.09.006.